Kidney/ Renal Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
12278A Clinical Urology Research Screening Protocol
11-0062 Long Term Database Collection for Renal Cell Carcinoma
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB13-1013 A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination With Crizotinib (PF-02341066) in Patients With Advanced Solid Tumors
Select
IRB13-0738 S0931: EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Select
IRB14-0105 A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3
Select
IRB14-0609 A Phase II Trial to Evaluate the Efficacy of AZD6094 (HPL-504) in Patients with Papillary Renal Cell Carcinoma (PRCC)

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team